Home » MERIT Trial Leaves Role of Pfizer’s Celsentri Unclear
MERIT Trial Leaves Role of Pfizer’s Celsentri Unclear
With Pfizer’s novel HIV treatment Celsentri failing to demonstrate non-inferiority to Bristol-Myers Squibb’s Sustiva in the MERIT trial, the drug’s chances of easily securing a first-line use indication look rather bleak.
Pharmaceutical Business Review
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May